Fibrinolyse intraventrikularer hamatome mit rt-PA

Translated title of the contribution: Fibrinolysis of intraventricular hematoma with tissue plasminogen activator

S. Schwarz, S. Schwab, H. H. Steiner, Daniel F Hanley, W. Hacke

Research output: Contribution to journalArticle

Abstract

Intraventricular administration of recombinant tissue plasminogen activator (rt-PA) is an experimental therapy to hasten the lysis of intraventricular hemorrhages. We report nine patients (7 male, 2 female, mean age 64a) with intracerebral hematoma with ventricular extension who were treated with intraventricular infusion of rt-PA (2-32 mg, mean dose 17 mg). In two patients, clinically significant bleeding complications were associated with the fibrinolytic therapy. In one of these patients, fibrinolytic therapy was stopped. Other complications could not be observed. In eight of all nine patients, a rapid and extensive reduction of the amount of intraventricular blood occurred. A persistent shunt became necessary in two patients. We conclude, that intraventricular fibrinolysis probably leads to a faster clearance of intraventricular blood. Despite of fibrinolytic treatment, a permanent shunt becomes necessary in some cases. Intraventricular fibrinolysis is a potentially hazardous therapy with the risks of bleeding complications and infection.

Original languageGerman
Pages (from-to)123-130
Number of pages8
JournalNervenarzt
Volume70
Issue number2
DOIs
StatePublished - Feb 1999

Fingerprint

Fibrinolysis
Tissue Plasminogen Activator
Hematoma
Thrombolytic Therapy
Hemorrhage
Intraventricular Infusions
Investigational Therapies
Therapeutics
Infection

Keywords

  • Intracerebral hemorrhage
  • Intraventricular hemorrhage
  • Tissue plasminogen activator
  • Ventricular drainage

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology

Cite this

Schwarz, S., Schwab, S., Steiner, H. H., Hanley, D. F., & Hacke, W. (1999). Fibrinolyse intraventrikularer hamatome mit rt-PA. Nervenarzt, 70(2), 123-130. https://doi.org/10.1007/s001150050412

Fibrinolyse intraventrikularer hamatome mit rt-PA. / Schwarz, S.; Schwab, S.; Steiner, H. H.; Hanley, Daniel F; Hacke, W.

In: Nervenarzt, Vol. 70, No. 2, 02.1999, p. 123-130.

Research output: Contribution to journalArticle

Schwarz, S, Schwab, S, Steiner, HH, Hanley, DF & Hacke, W 1999, 'Fibrinolyse intraventrikularer hamatome mit rt-PA', Nervenarzt, vol. 70, no. 2, pp. 123-130. https://doi.org/10.1007/s001150050412
Schwarz, S. ; Schwab, S. ; Steiner, H. H. ; Hanley, Daniel F ; Hacke, W. / Fibrinolyse intraventrikularer hamatome mit rt-PA. In: Nervenarzt. 1999 ; Vol. 70, No. 2. pp. 123-130.
@article{84dfd6c045c04f7bb105140c6da24b28,
title = "Fibrinolyse intraventrikularer hamatome mit rt-PA",
abstract = "Intraventricular administration of recombinant tissue plasminogen activator (rt-PA) is an experimental therapy to hasten the lysis of intraventricular hemorrhages. We report nine patients (7 male, 2 female, mean age 64a) with intracerebral hematoma with ventricular extension who were treated with intraventricular infusion of rt-PA (2-32 mg, mean dose 17 mg). In two patients, clinically significant bleeding complications were associated with the fibrinolytic therapy. In one of these patients, fibrinolytic therapy was stopped. Other complications could not be observed. In eight of all nine patients, a rapid and extensive reduction of the amount of intraventricular blood occurred. A persistent shunt became necessary in two patients. We conclude, that intraventricular fibrinolysis probably leads to a faster clearance of intraventricular blood. Despite of fibrinolytic treatment, a permanent shunt becomes necessary in some cases. Intraventricular fibrinolysis is a potentially hazardous therapy with the risks of bleeding complications and infection.",
keywords = "Intracerebral hemorrhage, Intraventricular hemorrhage, Tissue plasminogen activator, Ventricular drainage",
author = "S. Schwarz and S. Schwab and Steiner, {H. H.} and Hanley, {Daniel F} and W. Hacke",
year = "1999",
month = "2",
doi = "10.1007/s001150050412",
language = "German",
volume = "70",
pages = "123--130",
journal = "Der Nervenarzt",
issn = "0028-2804",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Fibrinolyse intraventrikularer hamatome mit rt-PA

AU - Schwarz, S.

AU - Schwab, S.

AU - Steiner, H. H.

AU - Hanley, Daniel F

AU - Hacke, W.

PY - 1999/2

Y1 - 1999/2

N2 - Intraventricular administration of recombinant tissue plasminogen activator (rt-PA) is an experimental therapy to hasten the lysis of intraventricular hemorrhages. We report nine patients (7 male, 2 female, mean age 64a) with intracerebral hematoma with ventricular extension who were treated with intraventricular infusion of rt-PA (2-32 mg, mean dose 17 mg). In two patients, clinically significant bleeding complications were associated with the fibrinolytic therapy. In one of these patients, fibrinolytic therapy was stopped. Other complications could not be observed. In eight of all nine patients, a rapid and extensive reduction of the amount of intraventricular blood occurred. A persistent shunt became necessary in two patients. We conclude, that intraventricular fibrinolysis probably leads to a faster clearance of intraventricular blood. Despite of fibrinolytic treatment, a permanent shunt becomes necessary in some cases. Intraventricular fibrinolysis is a potentially hazardous therapy with the risks of bleeding complications and infection.

AB - Intraventricular administration of recombinant tissue plasminogen activator (rt-PA) is an experimental therapy to hasten the lysis of intraventricular hemorrhages. We report nine patients (7 male, 2 female, mean age 64a) with intracerebral hematoma with ventricular extension who were treated with intraventricular infusion of rt-PA (2-32 mg, mean dose 17 mg). In two patients, clinically significant bleeding complications were associated with the fibrinolytic therapy. In one of these patients, fibrinolytic therapy was stopped. Other complications could not be observed. In eight of all nine patients, a rapid and extensive reduction of the amount of intraventricular blood occurred. A persistent shunt became necessary in two patients. We conclude, that intraventricular fibrinolysis probably leads to a faster clearance of intraventricular blood. Despite of fibrinolytic treatment, a permanent shunt becomes necessary in some cases. Intraventricular fibrinolysis is a potentially hazardous therapy with the risks of bleeding complications and infection.

KW - Intracerebral hemorrhage

KW - Intraventricular hemorrhage

KW - Tissue plasminogen activator

KW - Ventricular drainage

UR - http://www.scopus.com/inward/record.url?scp=0033037535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033037535&partnerID=8YFLogxK

U2 - 10.1007/s001150050412

DO - 10.1007/s001150050412

M3 - Article

C2 - 10098147

AN - SCOPUS:0033037535

VL - 70

SP - 123

EP - 130

JO - Der Nervenarzt

JF - Der Nervenarzt

SN - 0028-2804

IS - 2

ER -